<i>UGT1A1</i> Polymorphism for Irinotecan Dose Escalation in Patients with <i>BRAF</i>-Mutated Metastatic Colorectal Cancer Treated with First-Line Bevacizumab and FOLFIRI

<div>Kaplan–Meier survival curves for (a) progress-free survival and (b) overall survival stratified by tumor sidedness. A trend of favorable PFS and OS was observed in patients with right-sided mCRC.</div>

Journal of Oncology

fig3

Figure 3

Figure 3: <i>UGT1A1</i> Polymorphism for Irinotecan Dose Escalation in Patients with <i>BRAF</i>-Mutated Metastatic Colorectal Cancer Treated with First-Line Bevacizumab and FOLFIRI 

Figure 3 | UGT1A1 Polymorphism for Irinotecan Dose Escalation in Patients with BRAF-Mutated Metastatic Colorectal Cancer Treated with First-Line Bevacizumab and FOLFIRI 